Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma

Hepatology

Volumn 57, Issue 4, 2013, Pages 1448-1457

  Mizukoshi, Eishiro ^a   Yamashita, Tatsuya ^a   Arai, Kuniaki ^a   Sunagozaka, Hajime ^a   Ueda, Teruyuki ^a   Arihara, Fumitaka ^a   Kagaya, Takashi ^a   Yamashita, Taro ^a   Fushimi, Kazumi ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; TETRAMER; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; SUPPRESSOR CELL; T LYMPHOCYTE;

AGED; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 84876118103     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26153     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-1380.
3. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. HEPATOLOGY 2010; 52: 762-773.
4. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. HEPATOLOGY 2009; 49: 453-459.
5. den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64: 4024-4029.
6. Iida N, Nakamoto Y, Baba T, Nakagawa H, Mizukoshi E, Naito M, et al. Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC chemokine ligand 3/macrophage inflammatory protein-1alpha. Cancer Res 2010; 70: 6556-6565.
7. Araki T, Itai Y, Furui S, Tasaka A. Dynamic CT densitometry of hepatic tumors. AJR Am J Roentgenol 1980; 135: 1037-1043.
8. Japan LCSGo. Classification of Primary Liver Cancer. 2nd ed. [in English]. Tokyo, Japan: Kanehara & Co., Ltd.; 1997.
9. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994; 19: 1513-1520.
10. Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 2006; 118: 1194-1204.
11. Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. HEPATOLOGY 2006; 43: 1284-1294.
12. Mizukoshi E, Honda M, Arai K, Yamashita T, Nakamoto Y, Kaneko S. Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma. J Hepatol 2008; 49: 946-954.
13. Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. HEPATOLOGY 2011; 53: 1206-1216.
14. Ikeda-Moore Y, Tomiyama H, Miwa K, Oka S, Iwamoto A, Kaneko Y, et al. Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. J Immunol 1997; 159: 6242-6252.
15. Kuzushima K, Hayashi N, Kimura H, Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001; 98: 1872-1881.
16. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. 6th ed. New York, NY: Wiley-Liss; 2002.
17. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
18. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 2001; 166: 5300-5308.
19. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 2689-2697.
20. Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M, et al. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. HEPATOLOGY 2008; 48: 1821-1833.
21. Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA, Sugiyama Y. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett 1998; 433: 149-152.
22. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, et al. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000; 164: 2565-2574.
23. Frost M, Bobak JB, Gianani R, Kim N, Weinrich S, Spalding DC, et al. Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix. Am J Clin Pathol 2000; 114: 726-734.
24. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999; 59: 4056-4063.
25. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 3044-3048.
26. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-243.
27. Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 2006; 66: 1139-1146.
28. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29: 4828-4836.
29. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11: 805-812.